Clinical trials: Pemetrexed
Non-Small-Cell Lung Carcinoma
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
This is a Phase IIb/III randomized, double-blind, placebo-controlled study to compare the efficacy and safety of first-line therapy combined with TG4010 or placebo in stage IV non-small cell lung cancer (NSCLC).
- Trial name
- TIME (NCT01383148)
- Testing
- TG4010
- Where
- 72 sites in United States, Belgium and 8 more
- Volunteers
- 222 people
- Sponsor
- Transgene
Lung Cancer, Metastatic Cancer
Whole-Brain Radiation Therapy and Pemetrexed in Treating Patients With Brain Metastases From Non-Small Cell Lung Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Pemetrexed may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NRR (NCT00280748)
- Testing
- pemetrexed disodium, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-Small Cell Lung Cancer
A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
HS-10241, an oral and highly selective MET-TKI, may contribute to overcoming common acquired MET-based resistance mechanisms following prior EGFR-TKI monotherapy.
- Trial name
- NCT06110663
- Testing
- HS-10241+ Almonertinib, Pemetrexed + Cisplatin /Carboplatin
- Volunteers
- 314 people
- Sponsor
- Jiangsu Hansoh Pharmaceutical Co., Ltd.
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
This study will evaluate the safety, tolerability, and preliminary antitumor activity of CAN04 both as a monotherapy and in combination with standard of care treatment in subjects with solid cancer tumors.
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple Negative Breast Cancer, Colorectal Cancer
- Trial name
- CANFOUR (NCT03267316)
- Testing
- CAN04, Cisplatin, Gemcitabine
- Where
- 25 sites in Austria, Belgium and 9 more
- Volunteers
- 167 people
- Sponsor
- Cantargia AB
Reversible Pulpitis, Deep Carious Lesions
Comparative Evaluation of Calcium Silicate-doped Treated Dentin Matrix and Mineral Trioxide Aggregate as Miniature Pulpotomy Biomaterials in Deep Carious Lesions
AIM: To compare the efficacy of a Novel calcium silicate doped treated dentin matrix and Mineral Trioxide aggregate as biomaterials for miniature pulpotomy.
- Trial name
- hTDM (NCT07302438)
- Testing
- Calcium Silicate doped treated dentin matrix for miniature pulpotomy (CaSi+hTDM MP)., Mineral Trioxide Aggregate (MTA) for Miniature Pulpotomy
- Where
- 2 sites in India
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- All India Institute of Medical Sciences
Local Advanced Non-Small Cell Lung Cancer
Study of Concurrent Pemetrexed, Cisplatin and Radiotherapy in Local Advanced Non-Small Cell Lung Cancer
The purpose of this study is to determine the recommended dose of pemetrexed and the maximum tolerated dose of radiotherapy when using concurrent pemetrexed/cisplatin/radiotherapy in the patients with local advanced non-small…
- Trial name
- NCT00846443
- Testing
- Concurrent Pemetrexed, Cisplatin and Radiotherapy
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Fudan University
Metastatic Breast Cancer
Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients
This is a single-center, open, randomized, controlled phase 2 clinical trial designed to compare low-dose-bevacizumab and pemetrexed with TPC in metastatic HER2-negative breast cancer patients after failure of taxanes and…
- Trial name
- NCT02829008
- Testing
- low-dose-bevacizumab/pemetrexed, Treatment of physician's choice
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Chinese Academy of Medical Sciences
Lung Adenocarcinoma, Neutropenia
Vitamin Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy
Folic acid (FA; folate) in the dose of 350-1,000 μg daily should be supplemented, daily, starting 7 days before the first dose of pemetrexed based chemotherapy and should be continued while the patient is on therapy and for 21…
- Conditions
- Lung Adenocarcinoma, Neutropenia, Anemia, Thrombocytopenia
- Trial name
- PEMVITASTART (NCT02679443)
- Testing
- Folate and B12
- Where
- India
- Volunteers
- 161 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Advanced or Metastatic Solid Tumors, Non-Small Cell Lung Cancer
A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC
This research study is studying an investigational drug, NC318, as a possible treatment for subjects with advanced or metastatic non-small cell lung cancer in combination with chemotherapy
- Trial name
- NCT04430933
- Testing
- NC318, Pemetrexed/Carboplatin, Nab paclitaxel/Carboplatin
- Sponsor
- NextCure, Inc.
Solid Tumor Cancer, Chemotherapy Induced Neutropenia
A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy.
This study is a multi-cohort, open-label, multi-center exploratory clinical research designed to evaluate the efficacy and safety of Efbemalenograstim alfa Injection in preventing neutropenia (reduction in absolute neutrophil…
- Conditions
- Solid Tumor Cancer, Chemotherapy Induced Neutropenia, G-CSF
- Trial name
- EF-001 (NCT06649448)
- Testing
- Efbemalenograstim alfa Injection, carboplatin/cisplatin-etoposide, Carboplatin plus Paclitaxel
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Shandong Cancer Hospital and Institute
Non-Small Cell Lung Cancer, Carcinoma
Molecular Profiling in Lung Cancer Patients
The main purpose of this study of pemetrexed combined with cisplatin used as neoadjuvant chemotherapy (2 or 3 cycles) in participants with operable non-small cell lung cancer (NSCLC) is to look at various genes present in…
- Trial name
- NCT00191308
- Testing
- pemetrexed, cisplatin, Radical Non-Small Cell Lung Cancer (NSCLC) surgery
- Where
- 3 sites in Poland
- Volunteers
- 30 people
- Sponsor
- Eli Lilly and Company
Neoplasms
A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)
This is a first-in-human study evaluating the anti-T cell immunoglobulin and mucin containing protein-3 (TIM-3) antibody TSR-022.
- Trial name
- NCT02817633
- Testing
- TSR-022, Nivolumab, TSR-042
- Where
- 89 sites in United States, South Korea and 1 more
- Volunteers
- 463 people
- Sponsor
- Tesaro, Inc.
Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7
Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
This randomized phase II trial studies pemetrexed disodium and sunitinib malate to compare how well they work when given alone or together as second-line therapy in treating patients with stage IIIB or stage IV non-small cell…
- Conditions
- Recurrent Non-Small Cell Lung Carcinoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IV Non-Small Cell Lung Cancer AJCC v7
- Trial name
- NCT00698815
- Testing
- Laboratory Biomarker Analysis, Pemetrexed Disodium, Sunitinib Malate
- Where
- 129 sites in United States
- Volunteers
- 130 people
- Sponsor
- National Cancer Institute (NCI)
Cervical Cancer
SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
This study is a randomized, open-label, controlled, multicenter phase Ⅲ clinical trial, which aims to evaluate the efficacy and safety of SYS6002 versus investigator's choice of chemotherapy in the treatment of participants with…
- Trial name
- NCT07230626
- Testing
- SYS6002, Investigator's Choice of Chemotherapy
- Volunteers
- 412 people
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Advanced Non-squamous NSCLC
Anlotinib Plus Pemetrexed or Pemetrexed for Previously Untreated Elderly (>=70) or PS=2 Non-squamous NSCLC
Evaluate the efficacy and safety of Anlotinib plus Pemetrexed as the 1-line treatment of patients with Platinum intolerant advanced non-squamous NSCLC, with Pemetrexed control.
- Trial name
- NCT03768037
- Testing
- Anlotinib plus Pemetrexed, Pemetrexed
- Where
- China
- Volunteers
- 106 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-Small Cell Lung Cancer Metastatic
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
This is an open-label randomized, controlled, multicenter, phase II trial with two arms. Patients with metastatic TTF-1 negative, treatment-naive lung adenocarcinoma without actionable genomic alterations are randomized in a 1:1…
- Trial name
- ANTELOPE (NCT05689671)
- Testing
- Atezolizumab, Nab paclitaxel, Carboplatin
- Where
- 36 sites in Germany
- Volunteers
- 136 people
- Sponsor
- Nikolaj Frost MD
Cancer, Solid Tumor
First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors
The purpose of this study is to determine the safety, tolerability and efficacy of IBI308 monotherapy or in combination with chemotherapy in patients with certain types of advanced solid tumors.
- Trial name
- NCT02937116
- Testing
- IBI308, IBI308\Cisplatinum\Pemetrexed, IBI308\cisplatin\gemcitabine
- Where
- China
- Volunteers
- 233 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Toxicity, Non-small Cell Lung Cancer
Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients
The purpose of this study is to examine the efficacy and safety of gefitinib combinated with Pemetrexed/Cisplatin in advanced non-small cell lung cancer (NSCLC).
- Trial name
- NCT01192243
- Testing
- Gefitinib, Pemetrexed, Cisplatin or carboplatin
- Where
- China
- Volunteers
- 68 people
- Sponsor
- Fudan University
Non-Squamous Non-Small Cell Lung Cancer
A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer
This is a multicentre, randomized, double-blind, parallel-controlled integrated phase I/III clinical study to evaluate the similarity in efficacy, safety, PK profile, and immunogenicity of HLX17 vs.
- Trial name
- NCT06847334
- Testing
- HLX17, US-sourced Keytruda®, EU-sourced Keytruda®
- Volunteers
- 772 people
- Sponsor
- Shanghai Henlius Biotech
Non Small Cell Lung Cancer, Mesothelioma
Dose Individualization of Pemetrexed - IMPROVE-III
Rationale: Pemetrexed is a multi-targeted folate antagonist, which is primarily indicated for the treatment of advanced non-small cell lung cancer (NSCLC) and mesothelioma.
- Trial name
- IMPROVE-III (NCT03655834)
- Testing
- Pemetrexed
- Where
- 5 sites in Netherlands
- Volunteers
- 10 people
- Sponsor
- Radboud University Medical Center